Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUTO3 in Pediatric/Young Adult R/R B-ALL
NCT03289455Phase 2Completed
- Sponsor
- Autolus Therapeutics plc
- Start
- Jun 2017
- Primary completion
- May 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of AUTO3 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Autolus Therapeutics plc. Started Jun 2017; status: completed.
02
Drugs
AUTO3
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03289455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03289455.